This year has witnessed a number of key developments in the biosimilars space, including the approval of Celltrion’s Remicade biosimilar – Remsima – in South Korea, the regulatory submission of this product to the European Medicines Agency (with potential approval in 2013), ongoing evolution of the US biosimilars pathway and further deal-making by would-be biosimilar developers.

See on www.firstwordpharma.com